BioCryst Pharmaceuticals heads into its May 4 Q1 earnings call with short sellers rebuilding positions at pace — and options traders turning more defensive than at any point in recent memory.
The week's most striking development is the speed of the short rebuild. Short interest climbed roughly 24% over five trading days to end the week at 17.7% of the free float — jumping from around 14.3% on April 21 to 17.7% by April 28. That is a substantial one-week move for a stock sitting near $8.86. The ORTEX short score confirmed the pressure, rising to 64.6 by week's end from 60.1 a week earlier. What makes this interesting is the context: SI had already been falling steadily from a March peak near 19.4% of free float down to the mid-14% range, suggesting the mid-week surge represented a deliberate pre-earnings bet rather than a continuation of the prior unwind.
The borrow market tells a more complicated story. Cost to borrow collapsed — down 88% on the week to just 0.50% — after spiking sharply to nearly 5% in mid-April. That spike-and-collapse pattern points to a brief borrow squeeze that cleared itself: shorts who struggled to source stock at elevated rates in the April 17-21 window found ample supply once the panic subsided. Availability has tightened meaningfully from where it was, but remains in a range consistent with normal market conditions. The combination of cheap, available borrow and a rising short base suggests these are fresh, deliberate positions rather than a residual carry trade — traders are choosing to be short into the print.
Options positioning has also turned more cautious than at almost any point in the past year. The put/call ratio has climbed to 0.29, more than two standard deviations above its 20-day average of 0.23. That is the most defensive reading since the 52-week high of 0.41. The trend is clear in the daily data: the PCR sat below 0.21 through most of March and early April, then stepped sharply higher from mid-April onward. Options traders and short sellers are pointing in the same direction heading into earnings.
The Street, however, remains predominantly bullish on paper — though recent analyst data runs stale. The most recent action available, from January 2026, shows RBC Capital maintaining an Outperform while cutting its target from $14 to $13. That target looks generous given the current price of $8.86, and several other firms have targets ranging from $18 to $32, reflecting the gap between where analysts thought the stock could go and where it actually trades today. The mean consensus target is $21.40. Bulls point to Orladeyo's commercial momentum, the potential upside from the navenibart pipeline, and the company's recent acquisition of ATXS as diversifying assets. Bears flag competitive pressure in HAE from longer-acting injectables and execution risk on the pipeline — concerns that would concentrate around any Q1 revenue miss or guidance revision.
Insider selling adds a further note of caution. Over the past 90 days, insiders offloaded a net $4.7 million of stock. The former CEO Jon Stonehouse sold nearly 306,000 shares in early March at $8.64, and the Chief Legal Officer sold $1.4 million worth in mid-March. These are not trivial sums relative to the stock's recent trading range. It doesn't necessarily signal anything definitive — executives sell for many reasons — but the collective direction of insider flows is consistent with the broader positioning picture.
The last earnings print, in February 2026, produced a 15.9% one-day gain — a strong reminder that the shorts are not betting on an inevitability. Q1 revenue from Orladeyo versus any commentary on navenibart's timeline is where the next week's action will pivot.
See the live data behind this article on ORTEX.
Open BCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
